A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

ID Number 17-0672

Principal Investigator(s)
Charissa Chang

Department(s) or Division(s)
Liver Diseases


The purpose of this study is to evaluate whether selonsertib (SEL, previously known as GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) fibrosis and to assess the safety and tolerability of SEL in subjects with NASH and bridging (F3) fibrosis.

Contact Information
Jonathan Kessler
(212) 241-9264

Recruiting Patients: Yes